Golden
Novo Biosciences

Novo Biosciences

A pharmaceutical company that uses a zebrafish drug-screening platform to find drug candidate molecules that have the capacity to promote regeneration of tissues. Their drug candidate MSI-1436 is being developed and tested for the treatment of heart disease, Duchenne Muscular Dystrophy and diabetic nephropathy.

All edits

Edits on 14 Sep 2019
Julius John Villarisco
Julius John Villarisco approved a suggestion from Golden's AI on 14 Sep 2019 1:47 pm
Edits made to:
Article (+6/-6 characters)

Article

Voot Yin, Novo Bioscience’s chief scientific officer was awarded a two-year $1.5 million Small Business Innovation Research grant in 2017 from the National Heart, Lung and Blood Institute, an institute of the National Institutes of HealthHealth (NIH), to study trodusquemine in the pig. The pig heart closely resembles that of a human. The drug is being tested as a treatment for acute heart attack and also for chronic heart injury, Duchenne muscular dystrophy, skeletal muscle injury and spinal cord damage. 

Edits on 14 Sep 2019
Julius John Villarisco
Julius John Villarisco approved a suggestion from Golden's AI on 14 Sep 2019 9:07 am
Edits made to:
Article (+15/-15 characters)

Article

Novo Biosciences was founded by Kevin Strange and Voot P. Yin. Strange was president of Mount Desert Island (MDI) Biological Lab from 2009 to 2016 and and Yin was an MDI Biological Laboratory faculty member. Together along with Michael ZasloffMichael Zasloff of Georgetown University, they are co-inventors of the drug candidate MSI-1436, also called trodusquemine. Strange stepped down as president of MDI Bio Lab to pursue development of MSI-1436 as CEO of Novo Biosciences. 

Julius John Villarisco
Julius John Villarisco approved a suggestion from Golden's AI on 14 Sep 2019 7:49 am
Edits made to:
Article (+4/-4 characters)

Article

Voot Yin, Novo Bioscience’s chief scientific officer was awarded a two-year $1.5 million Small Business Innovation Research grant in 2017 from the National Heart, LungLung and Blood Institute, an institute of the National Institutes of Health (NIH), to study trodusquemine in the pig. The pig heart closely resembles that of a human. The drug is being tested as a treatment for acute heart attack and also for chronic heart injury, Duchenne muscular dystrophy, skeletal muscle injury and spinal cord damage. 

Julius John Villarisco
Julius John Villarisco approved a suggestion from Golden's AI on 14 Sep 2019 7:02 am
Edits made to:
Article (+19/-19 characters)

Article

Novo Biosciences was founded by Kevin Strange and Voot P. Yin. Strange was president of Mount Desert IslandMount Desert Island (MDI) Biological Lab from 2009 to 2016 and and Yin was an MDI Biological Laboratory faculty member. Together along with Michael Zasloff of Georgetown University, they are co-inventors of the drug candidate MSI-1436, also called trodusquemine. Strange stepped down as president of MDI Bio Lab to pursue development of MSI-1436 as CEO of Novo Biosciences. 

Julius John Villarisco
Julius John Villarisco approved a suggestion from Golden's AI on 14 Sep 2019 6:52 am
Edits made to:
Article (+9/-9 characters)

Article

The approach of Novo Bioscience is to study animals with regenerative capabilities and with whom humans share most genes in order to identify regenerative medicine drug targets. The company uses zebrafishzebrafish, an aquarium fish, as a drug-screening platform. Zebrafish regenerate hearts, spinal cords, kidneys, pancreases and appendages after damage. Humans share the same fundamental genetic machinery that enables zebrafish and other animal to regrow tissues, organs and body parts. Novo Biosciences is investigating the possibility of finding drugs that can unlock innate regenerative abilities in humans or drugs that can reset genetic machinery to allow regeneration. 

Julius John Villarisco
Julius John Villarisco approved a suggestion from Golden's AI on 14 Sep 2019 6:42 am
Edits made to:
Article (+21/-21 characters)

Article

Novo Biosciences was founded by Kevin Strange and Voot P. Yin. Strange was president of Mount Desert Island (MDI) Biological Lab from 2009 to 2016 and and Yin was an MDI Biological Laboratory faculty member. Together along with Michael Zasloff of Georgetown UniversityGeorgetown University, they are co-inventors of the drug candidate MSI-1436, also called trodusquemine. Strange stepped down as president of MDI Bio Lab to pursue development of MSI-1436 as CEO of Novo Biosciences. 

Julius John Villarisco
Julius John Villarisco approved a suggestion from Golden's AI on 13 Sep 2019 7:38 pm
Edits made to:
Article (+21/-21 characters)

Article

The approach of Novo Bioscience is to study animals with regenerative capabilities and with whom humans share most genes in order to identify regenerative medicineregenerative medicine drug targets. The company uses zebrafish, an aquarium fish, as a drug-screening platform. Zebrafish regenerate hearts, spinal cords, kidneys, pancreases and appendages after damage. Humans share the same fundamental genetic machinery that enables zebrafish and other animal to regrow tissues, organs and body parts. Novo Biosciences is investigating the possibility of finding drugs that can unlock innate regenerative abilities in humans or drugs that can reset genetic machinery to allow regeneration. 

Edits on 10 Sep 2019
Meredith Hanel
Meredith Hanel edited on 10 Sep 2019 2:02 am
Edits made to:
Description (+312 characters)
Article (+668 characters)
Topic thumbnail

Novo Biosciences

A pharmaceutical company that uses a zebrafish drug-screening platform to find drug candidate molecules that have the capacity to promote regeneration of tissues. Their drug candidate MSI-1436 is being developed and tested for the treatment of heart disease, Duchenne Muscular Dystrophy and diabetic nephropathy.

Article

The approach of Novo Bioscience is to study animals with regenerative capabilities and with whom humans share most genes in order to identify regenerative medicine drug targets. The company uses zebrafish, an aquarium fish, as a drug-screening platform. Zebrafish regenerate hearts, spinal cords, kidneys, pancreases and appendages after damage. Humans share the same fundamental genetic machinery that enables zebrafish and other animal to regrow tissues, organs and body parts. Novo Biosciences is investigating the possibility of finding drugs that can unlock innate regenerative abilities in humans or drugs that can reset genetic machinery to allow regeneration. 



Meredith Hanel
Meredith Hanel edited on 10 Sep 2019 1:42 am
Edits made to:
Article (+177/-342 characters)

Article

Novo received a Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health in 2017 to pursue MSI-1436 for treatment of heart damage cause by acute heart attack. The drug is also being tested for chronic heart injury, Duchenne muscular dystrophy, skeletal muscle injury and spinal cord damage. 



Voot Yin, Novo Bioscience’s chief scientific officer was awarded a two-year $1.5 million Small Business Innovation Research grant in 2017 from the National Heart, Lung and Blood Institute, an institute of the National Institutes of Health (NIH), to study trodusquemine in the pig. The pig heart closely resembles that of a human. The drug is being tested as a treatment for acute heart attack and also for chronic heart injury, Duchenne muscular dystrophy, skeletal muscle injury and spinal cord damage. 

Meredith Hanel
Meredith Hanel edited on 10 Sep 2019 1:33 am
Edits made to:
Infobox (+6 properties)
Article (+1406 characters)
People (+2 rows) (+4 cells) (+65 characters)

Article

Novo Biosciences was founded by Kevin Strange and Voot P. Yin. Strange was president of Mount Desert Island (MDI) Biological Lab from 2009 to 2016 and and Yin was an MDI Biological Laboratory faculty member. Together along with Michael Zasloff of Georgetown University, they are co-inventors of the drug candidate MSI-1436, also called trodusquemine. Strange stepped down as president of MDI Bio Lab to pursue development of MSI-1436 as CEO of Novo Biosciences. 



Novo received a Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health in 2017 to pursue MSI-1436 for treatment of heart damage cause by acute heart attack. The drug is also being tested for chronic heart injury, Duchenne muscular dystrophy, skeletal muscle injury and spinal cord damage. 

...

Voot Yin, Novo Bioscience’s chief scientific officer was awarded a two-year $1.5 million Small Business Innovation Research grant in 2017 from the National Heart, Lung and Blood Institute, an institute of the National Institutes of Health (NIH), to study trodusquemine in the pig. The pig heart closely resembles that of a human. 

In February, 2019, Yin was awarded a $100,000 pilot grant to study the efficacy of trodusquemine as a regenerative medicine therapy for diabetic kidney disease. Novo will study trodusquemine in mice with kidney abnormalities similar to those in human diabetic nephropathy.

People

Name
Role
LinkedIn

Kevin Strange, Ph.D.

CEO, Co-Founder



Voot Yin, Ph.D.

CSO, Co-Founder



Infobox

Meredith Hanel"Initial topic creation"
Meredith Hanel created this topic on 9 Sep 2019 2:24 pm
Edits made to:
Topic thumbnail

 Novo Biosciences

A pharmaceutical company that uses a zebrafish drug-screening platform to find drug candidate molecules that have the capacity to promote regeneration of tissues. Their drug candidate MSI-1436 is being developed and tested for the treatment of heart disease, Duchenne Muscular Dystrophy and diabetic nephropathy.

No more activity to show.